|
|
|
| Effect of Amoxicillin,Lansoprazole,Clarithromycin Combined With Clostridium Butyricum on Serum Inflammatory Factors in Children With Chronic Gastritis and HP Infection |
| Liu Juan, Yang jun, Sun Lu |
| Department of Pharmacy,Kaifeng People's Hospital,Kaifeng 475001,China |
|
|
|
|
Abstract Objective To study the effect of amoxicillin,lansoprazole,clarithromycin combined with clostridium butyricum on serum inflammatory factors in children with chronic gastritis and HP infection. Methods A total of 80 children with chronic gastritis complicated with HP infection were randomly divided into control group and study group,40 cases in each group.The control group was treated with the traditional triple therapy of amoxicillin + lansoprazole + clarithromycin,and the study group was given the treatment of clostridium butyricum on the basis of the control group.The treatment course was 14 days.Gastrointestinal symptom rating score（GSRS）was used to evaluate the gastrointestinal symptoms of the children,and the HP eradication rate,serum inflammatory factor levels [high sensitivity C-reactive protein（CRP）,interleukin-6（IL-6）,interleukin-8（IL-8）]and gastrointestinal adverse reactions of the two groups were analyzed and compared. Results After treatment,the GSRS score of the study group was significantly lower than that of the control group（P<0.05）.The eradication rate of HP in the study group was 87.5%,which was significantly higher than that of the control group（67.5%）（P<0.05）.The levels of CRP,IL-6 and IL-8 in the study group after treatment were lower than those in the control group（P<0.05）.The incidence of digestive system adverse reactions in the study group was 17.5%,which was lower than that of the control group（52.5%）（P<0.05）. Conclusion The application of amoxicillin,lansoprazole,clarithromycin combined with clostridium butyricum in the treatment of children with chronic gastritis with HP infection can effectively alleviate the symptoms of chronic gastritis,improve the eradication rate of HP,reduce the level of serum inflammatory factors,and reduce adverse drug reactions.
|
|
Received: 20 May 2021
|
|
|
|
|
|
[1] 崔云,陆诗媛,陈萦晅,等.慢性胃炎的病理诊断[J].临床荟萃,2019,34(5):399-402.
[2] 冉丹,吴寒,张振玉.东盟国家幽门螺杆菌感染的处理:曼谷共识报告[J].胃肠病学和肝病学杂志,2019,28(5):481-488.
[3] 王春燕,李胜棉.2017幽门螺杆菌感染诊治相关国内外指南更新[J].河北医科大学学报,2019,40(2):125-127.
[4] 全国中西医整合幽门螺杆菌处理共识专家组.全国中西医整合治疗幽门螺杆菌相关"病-证"共识[J].中华健康管理学杂志,2018,12(5):393-402.
[5] 熊华,房静远.幽门螺杆菌胃炎的诊断与治疗[J].胃肠病学,2018,23(11):641-645.
[6] 杨雪,高采平,张颖慧,等.嗜酸乳杆菌联合优化四联方案根除难治性幽门螺杆菌的疗效[J].四川医学,2020,41(11):1147-1151.
[7] 程进伟,余志金,陈惠新.调节肠道微生态对胃食管反流病与肠易激综合征重叠症患者临床症状及胃肠道功能的影响[J].广州医科大学学报,2018,46(4):28-31.
[8] 黄晓娟,郭小陪,延喜胜.分阶段服用奥美拉唑联合抗菌药物治疗Hp感染活动性慢性胃炎的效果观察[J].贵州医药,2021,45(1):31-32.
[9] 王雪,李异玲.幽门螺杆菌感染诊断方法的研究进展[J].医学综述,2020,26(5):955-959.
[10] 胡奕,吕农华.幽门螺杆菌感染:认清危害,提高防控水平[J].胃肠病学,2020,25(5):257-261.
[11] 霍江波,于淑霞,陈娟,等.雷贝拉唑、胶体果胶铋联合两种抗生素治疗HP相关性胃炎的效果观察[J].解放军预防医学杂志,2019,37(5):139-140. |
| [1] |
. [J]. journal1, 2022, 42(4): 136-137. |
| [2] |
. [J]. journal1, 2022, 42(3): 134-135. |
| [3] |
Cai Lixia. A Comparative Study of Effects of Standard Triple Therapy and Sequential Triple Therapy on the Levels of Serum Inflammatory Factors in Children Patients With Hp Infection[J]. journal1, 2021, 41(4): 19-20. |
| [4] |
. [J]. journal1, 2021, 41(4): 78-78. |
| [5] |
. [J]. journal1, 2021, 41(3): 136-137. |
|
|
|
|
2022, Vol. 42 
